NON SMALL CELL LUNG CANCER NSCLC

This study tests a vaccine designed to help the immune system recognize and attack non-small cell lung cancer. About 30 adults with early or locally advanced lung cancer will receive the vaccine every 3 weeks for 3 doses, with optional yearly boosters for up to 5 years. The goal …

This study tests an experimental drug called RMC-6236 in about 754 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS gene mutations. The main goals are to check safety and find the right dose. This is an early-phase trial, so it foc…

This study reviews medical records of 100 adults in Taiwan with early-stage non-small cell lung cancer who received nivolumab combined with chemotherapy before surgery. The goal is to see how well this treatment shrinks tumors and improves outcomes, and to check for side effects.…

This early-stage study tests a new drug called KO-2806 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if the drug can shrink tumors when used alone or with other cancer medicines. About 300 participan…

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another c…

This study tests a new drug called GTAEXS617 in 230 adults with advanced solid tumors, including lung, breast, ovarian, pancreatic, and head and neck cancers. The goal is to check the drug's safety, how the body processes it, and whether it can shrink tumors. Participants must ha…

This study looks at people with advanced stage IV non-small cell lung cancer that has spread. After initial drug therapy (chemo, immunotherapy, or targeted therapy) works well, half the participants will also get surgery or radiation to remove remaining tumor spots. The goal is t…

This study is a survey in Japan of the drug Brigatinib for people with a specific type of non-small cell lung cancer. The main goal is to check for lung-related side effects over one year. About 500 participants will take the drug as part of their normal care, and doctors will re…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors (like lung, head and neck, pancreatic, or kidney cancer). The drug is designed to help the immune system fight cancer by targeting a protein called CD73 and delivering a modified immune s…

This early-phase trial tests a new drug called TH9619 in 43 adults with advanced solid tumors (colorectal, head and neck, lung, or stomach cancer) that have not responded to prior treatment. The main goal is to find a safe dose and check for side effects. Researchers will also wa…

This phase 3 study tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer than pembrolizumab alone. The trial enrolls about 614 adults whose tumors have high PD-L1 levels (50…

This phase 3 study compares a new drug called pumitamig to the current standard drug durvalumab in people with stage III lung cancer that cannot be removed by surgery. Participants must have completed chemotherapy and radiation without their cancer getting worse. The main goal is…

This study tests a new drug, WSD0922-FU, combined with the standard drug osimertinib for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations). The goal is to see if the combination is safe and can shrink tumors, especially in patients…

This study tests two experimental drugs, elironrasib and daraxonrasib, alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if these drugs are safe and can shrink or control tumors. About 534 adults with lung, colorec…

This study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein called CEACAM5. The drug is designed to deliver a chemotherapy-like payload directly to cancer cells. The trial aims to see i…

This study tests new drugs called RAS(ON) inhibitors in people with a type of lung cancer that has a RAS mutation. The goal is to see if these drugs are safe and can shrink tumors. About 616 adults with advanced lung cancer will receive the drugs alone or with standard treatments…

This study tests a new drug called RMC-5127 in people with advanced solid tumors that have a specific KRAS G12V gene change. The drug is given alone or with other medicines to see if it is safe and can shrink tumors. About 574 adults who have already tried other treatments will t…

This study tests whether the drug taletrectinib can prevent lung cancer from returning in people with a specific genetic marker (ROS1) after their tumor has been surgically removed. About 180 adults with stage IB to IIIA non-small cell lung cancer will receive either taletrectini…

This study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have tried at least one prior therapy. The main goals are to find a safe dose and check for early signs of tumor shrinkage. About 27 adults will…

This study tests a new drug called IDE574, which targets specific enzymes that help cancer cells grow. It is for people with advanced solid tumors (like lung, prostate, or colorectal cancer) or a type of breast cancer called ER+, HER2-. The trial has two parts: one where IDE574 i…

This study tests a new drug called Rina-S in about 240 people with advanced non-small cell lung cancer. The goal is to see if the drug can shrink tumors or slow the cancer's growth. All participants receive the active drug, and treatment may continue as long as it helps and side …

This study tests a combination of experimental drugs (RAS(ON) inhibitors plus ivonescimab) in adults with advanced solid tumors that have a RAS mutation. The goal is to see if the combination is safe and can shrink or control tumors. About 370 participants whose cancer has worsen…

This study is for people with stage III lung cancer whose tumor has come back in the chest after previous treatment with chemotherapy, radiation, and the drug durvalumab. Researchers want to see if giving radiation again followed by two drugs (durvalumab and ceralasertib) is safe…

This study tests a new drug, datopotamab deruxtecan (Dato-DXd), against a standard chemotherapy (docetaxel) in 400 people with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated. The cancer must have a specific marker called TROP2 and no …

This early-stage study tests gilteritinib, a drug already used for a type of leukemia, in people with a specific kind of lung cancer (ALK-positive NSCLC) that has stopped responding to standard treatments. About 40 adults will take the drug daily to see if it is safe and tolerabl…

This early-stage study tests a new drug called IDE892, alone or with other medicines, in people with advanced solid tumors that lack a gene called MTAP. The goal is to see if the drug is safe and can shrink tumors. About 260 adults with certain cancers (like lung, stomach, bladde…

This early-phase study tests a new experimental drug (LB-LR1109) alone or combined with atezolizumab in people with advanced solid tumors, including lung, head and neck, kidney, bladder, and skin cancers. The main goals are to find safe doses and understand side effects. About 76…

This early-stage study tests a new drug called BMS-986463 in people with advanced ovarian, uterine, or lung cancers that have spread and cannot be removed by surgery. The main goals are to check the drug's safety and find the best dose. About 240 participants will receive the dru…

This study is testing a new experimental drug called BMS-986523, given alone or with other cancer medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 252 adult…

This early-stage study tests an experimental drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The drug works by boosting the immune system to fight tumors. The main goals are to check safety and find the right dose, with a later …

This early-stage trial tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their gro…

This study compares a new drug called pumitamig to the standard treatment pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer whose tumors have high levels of a protein called PD-L1. The goal is to see if pumitamig works better at stopping cancer growth a…

This study compares two first-line treatments for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and no PD-L1 protein. One group gets the targeted pill sotorasib plus chemotherapy; the other gets the immunotherapy pembrolizumab plus chemoth…

This study tests a new drug called STX-241 in people with advanced non-small cell lung cancer that has stopped responding to standard targeted therapies. The drug is designed to reach the brain and attack cancer cells with specific genetic changes. The trial will check safety, fi…

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The drug targets a protein called HER3 found on some cancer cells. About 740 adults with various cancers like lung, breast, or melanoma w…

This study tests a treatment using donor immune cells (CAR-NK cells) designed to attack cancer. The specific target on the cancer cells is chosen based on a biopsy of the tumor or a blood test. The goal is to see if this approach is safe and can shrink or control advanced solid t…

This study tests a new drug called JYP0015 in adults with advanced solid tumors that have a specific genetic change called RAS mutation. The goal is to see if the drug is safe and can shrink tumors. About 210 people with pancreatic, lung, or colorectal cancer will take part.

This study tests an inhaled form of the drug azacytidine, given alongside standard chemotherapy and immunotherapy, for people with early-stage non-small cell lung cancer that can be removed by surgery. The goal is to find the safest and most effective dose and see if this combina…

This study explores whether genetic material from lung cancer cells can be collected from a lung wash (bronchoalveolar lavage) instead of a traditional biopsy. Researchers will compare the genetic test results from the wash fluid with those from standard biopsy samples in 10 peop…

This study tests a special dye called LS301-IT that makes lung cancer cells glow during surgery. About 35 adults with early-stage lung cancer will receive the dye before their tumor-removal surgery. The goal is to see if the dye helps surgeons find cancer that is hard to see with…

This study tests whether using an incentive spirometer—a device that encourages deep breathing—can lower the risk of lung inflammation (pneumonitis) in people with advanced lung cancer receiving chemotherapy and radiation. About 100 participants will use the device 10 times every…

This early-phase study is testing a new substance called RAD301 to see how it moves through the body and how much radiation it gives off. It involves 9 people: healthy volunteers and patients with certain cancers like pancreatic, lung, or ovarian cancer. The goal is to measure sa…

This study is observing how lung cancer patients respond to the drug Tislelizumab in real-world clinics, not a controlled lab setting. Researchers will track survival, side effects, and quality of life in 240 participants across Germany and Austria. The goal is to understand how …

This study interviews 55 people — patients with early-stage lung cancer and their doctors — to learn what matters most when choosing treatment. Researchers want to understand preferences and priorities to help guide future care decisions. No new drugs or treatments are being test…